p38 MAP kinase regulates BMP-4-stimulated VEGF synthesis via p70 S6 kinase in osteoblasts

Am J Physiol Endocrinol Metab. 2003 Jun;284(6):E1202-9. doi: 10.1152/ajpendo.00300.2002. Epub 2003 Mar 11.

Abstract

We previously reported that p70 S6 kinase takes part in bone morphogenetic protein-4 (BMP-4)-stimulated vascular endothelial growth factor (VEGF) synthesis in osteoblast-like MC3T3-E1 cells. Recently, we showed that BMP-4-induced osteocalcin synthesis is regulated by p44/p42 MAP kinase and p38 MAP kinase in these cells. In the present study, we investigated whether the MAP kinases are involved in the BMP-4-stimulated synthesis of VEGF in MC3T3-E1 cells. PD-98059 and U-0126, inhibitors of the upstream kinase of p44/p42 MAP kinase, failed to affect BMP-4-stimulated VEGF synthesis. SB-203580 and PD-169316, inhibitors of p38 MAP kinase, significantly reduced VEGF synthesis, whereas SB-202474, a negative control for p38 MAP kinase inhibitor, had little effect on VEGF synthesis. The BMP-4-stimulated phosphorylation of p38 MAP kinase was not affected by rapamycin, an inhibitor of p70 S6 kinase. On the contrary, SB-203580 and PD-169316 reduced the BMP-4-stimulated phosphorylation of p70 S6 kinase. In addition, anisomycin, an activator of p38 MAP kinase, phosphorylates p70 S6 kinase, and the phosphorylation was suppressed by SB-203580. LY-294002, an inhibitor of phosphatidylinositol 3-kinase, failed to suppress the phosphorylation of p38 MAP kinase induced by BMP-4. Not BMP-4 but anisomycin weakly induced the phosphorylation of phosphoinositide-dependent kinase-1. However, anisomycin had little effect on phosphorylation of either Akt or the mammalian target of rapamycin. Taken together, our results suggest that p38 MAP kinase functions in BMP-4-stimulated VEGF synthesis as a positive regulator at a point upstream from p70 S6 kinase in osteoblasts.

MeSH terms

  • Animals
  • Anisomycin / pharmacology
  • Anti-Bacterial Agents / pharmacology
  • Blotting, Western
  • Bone Morphogenetic Protein 4
  • Bone Morphogenetic Proteins / pharmacology*
  • Butadienes / pharmacology
  • Cell Line
  • Chromones / pharmacology
  • Endothelial Growth Factors / biosynthesis*
  • Enzyme-Linked Immunosorbent Assay
  • Flavonoids / pharmacology
  • Imidazoles / pharmacology
  • Intercellular Signaling Peptides and Proteins / biosynthesis*
  • Lymphokines / biosynthesis*
  • Mice
  • Mitogen-Activated Protein Kinases / physiology*
  • Morpholines / pharmacology
  • Nitriles / pharmacology
  • Osteoblasts / enzymology*
  • Phosphorylation
  • Protein Biosynthesis
  • Protein Synthesis Inhibitors / pharmacology
  • Proteins / analysis
  • Pyridines / pharmacology
  • Ribosomal Protein S6 Kinases, 70-kDa / metabolism*
  • Sirolimus / pharmacology
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Anti-Bacterial Agents
  • Bmp4 protein, mouse
  • Bone Morphogenetic Protein 4
  • Bone Morphogenetic Proteins
  • Butadienes
  • Chromones
  • Endothelial Growth Factors
  • Flavonoids
  • Imidazoles
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Morpholines
  • Nitriles
  • Protein Synthesis Inhibitors
  • Proteins
  • Pyridines
  • U 0126
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Anisomycin
  • Ribosomal Protein S6 Kinases, 70-kDa
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Sirolimus